CoChat

Integral Characterization of Defective BDNF/TrkB Signalling in Neurological and Psychiatric Disorders Leads the Way to New Therapies

Open access
Tejeda, Gonzalo, Díaz-Guerra, Margarita · 2017 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 211 of the 212 references it cites were found in a registry or an index.

Abstract

Enhancement of brain-derived neurotrophic factor (BDNF) signalling has great potential in therapy for neurological and psychiatric disorders. This neurotrophin not only attenuates cell death but also promotes neuronal plasticity and function. However, an important challenge to this approach is the persistence of aberrant neurotrophic signalling due to a defective function of the BDNF high-affinity receptor, tropomyosin-related kinase B (TrkB), or downstream effectors. Such changes have been already described in several disorders, but their importance as pathological mechanisms has been frequently underestimated. This review highlights the relevance of an integrative characterization of aberrant BDNF/TrkB pathways for the rational design of therapies that by combining BDNF and TrkB targets could efficiently promote neurotrophic signalling.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms18020268

Cites

211 of 211 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Function of BDNF/TrkB signalling in the CNS. BDNF binding to TrkB-FL in neurons (left diagram) induces receptor homodimerization and activation, triggering three main signalling pathways: MAPK/ERK (blue), PI3K (pink) and PLCγ (yellow), which regulate several processes central to neuronal function. The ligand-receptor complex can internalize and continue functioning in signalling endosomes. Alternatively, TrkB-T1 can form heterodimers with TrkB-FL and block its transduction cascades. TrkB-T1 is also involved in the regulation of local BDNF concentration (upper diagram) and cell morphology, both in neurons and astrocytes (respectively, left and right diagrams). P, phosphorylation sites important for receptor activation.
Figure 1 Function of BDNF/TrkB signalling in the CNS. BDNF binding to TrkB-FL in neurons (left diagram) induces receptor homodimerization and activation, triggering three main signalling pathways: MAPK/ERK (blue), PI3K (pink) and PLCγ (yellow), which regulate several processes central to neuronal function. The ligand-receptor complex can internalize and continue functioning in signalling endosomes. Alternatively, TrkB-T1 can form heterodimers with TrkB-FL and block its transduction cascades. TrkB-T1 is also involved in the regulation of local BDNF concentration (upper diagram) and cell morphology, both in neurons and astrocytes (respectively, left and right diagrams). P, phosphorylation sites important for receptor activation.CC BY · PubMed Central
Figure 2 Dysfunction of BDNF/TrkB signalling during stroke. Excitotoxicity produced by overstimulation of the NMDARs (a) induces several mechanisms that dysregulate BDNF/TrkB signalling. The inversion of the physiological ratio of TrkB mRNA isoforms (b) and TrkB-FL cleavage by calpain (c) reduce the availability of the catalytic receptor and increase the dominant-negative forms. Furthermore, TrkB-FL and TrkB-T1 undergo a sequential cleavage first by metalloproteinases (d) and then by γ-secretases (e) that shed the receptor ectodomains, which then act as BDNF scavengers (f); BDNF can be further sequestered by increased expression of p75NTR (g); Consequently, neurotrophic signalling is impaired, a situation aggravated even further by Shp-2 dephosphorylation of TrkB-FL at Tyr515 (h); Neurons in the peri-infarct area promote a survival response as a compensatory mechanism to brain damage and increase the expression of BDNF (i); CTF, C-terminal fragment; ECD, extracellular domain; f32, TrkB-FL calpain-fragment of 32 kDa; ICD, intracellular domain; tTrkB, calpain-truncated TrkB-FL.
Figure 2 Dysfunction of BDNF/TrkB signalling during stroke. Excitotoxicity produced by overstimulation of the NMDARs (a) induces several mechanisms that dysregulate BDNF/TrkB signalling. The inversion of the physiological ratio of TrkB mRNA isoforms (b) and TrkB-FL cleavage by calpain (c) reduce the availability of the catalytic receptor and increase the dominant-negative forms. Furthermore, TrkB-FL and TrkB-T1 undergo a sequential cleavage first by metalloproteinases (d) and then by γ-secretases (e) that shed the receptor ectodomains, which then act as BDNF scavengers (f); BDNF can be further sequestered by increased expression of p75NTR (g); Consequently, neurotrophic signalling is impaired, a situation aggravated even further by Shp-2 dephosphorylation of TrkB-FL at Tyr515 (h); Neurons in the peri-infarct area promote a survival response as a compensatory mechanism to brain damage and increase the expression of BDNF (i); CTF, C-terminal fragment; ECD, extracellular domain; f32, TrkB-FL calpain-fragment of 32 kDa; ICD, intracellular domain; tTrkB, calpain-truncated TrkB-FL.CC BY · PubMed Central
Figure 3 Dysfunction of BDNF/TrkB signalling in AD. Patients of AD show a decrease in BDNF levels in several brain areas due to a diminished gene expression (a). The consequent reduction in neurotrophic signalling results in the activation of GSK3β which contributes to tau hyperphosphorylation (b); Moreover, expression of truncated TrkB isoforms is favoured in AD brains by the action of transcription factor SRSF3 (c); Aβ peptide additionally promotes the activities of GSK3β and calpain, which cleaves TrkB-FL receptor near the receptor Shc docking site (d); Additionally, Aβ decreases CREB activity by several mechanisms including a reduction of NMDAR levels (e) and increased PP1 action. f32, TrkB-FL calpain fragment of 32 kDa; P, phosphorylation of tau residues; tTrkB, calpain-truncated TrkB-FL.
Figure 3 Dysfunction of BDNF/TrkB signalling in AD. Patients of AD show a decrease in BDNF levels in several brain areas due to a diminished gene expression (a). The consequent reduction in neurotrophic signalling results in the activation of GSK3β which contributes to tau hyperphosphorylation (b); Moreover, expression of truncated TrkB isoforms is favoured in AD brains by the action of transcription factor SRSF3 (c); Aβ peptide additionally promotes the activities of GSK3β and calpain, which cleaves TrkB-FL receptor near the receptor Shc docking site (d); Additionally, Aβ decreases CREB activity by several mechanisms including a reduction of NMDAR levels (e) and increased PP1 action. f32, TrkB-FL calpain fragment of 32 kDa; P, phosphorylation of tau residues; tTrkB, calpain-truncated TrkB-FL.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 211 references

Cited by

See all 128

Metadata

Authors
Tejeda, G., & Díaz-Guerra, M.
Affiliations
  • Consejo Superior de Investigaciones Científicas (ES)
  • Instituto de Investigaciones Biomédicas “Alberto Sols”, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Arturo Duperier 4, 28029 Madrid, Spain
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2017-01-28
Volume
18
Issue
2
Pages
268
ISSN
1422-0067 (ISSN-L)
OpenAlex
W2581435615
Cited by
126
References
212
Citations by year
2026: 8 · 2025: 13 · 2024: 16 · 2023: 16 · 2022: 13 · 2021: 13 · 2020: 20 · 2019: 13 · 2018: 10 · 2017: 4
FWCI
1.58
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
  • DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion, cc-by)
Funders
  • Ministerio de Economía y Competitividad, Spain (BFU2013-43808-R)
  • Fundación Mutua Madrileña, Spain (201322001)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
brain-derived neurotrophic factor, TrkB receptor, BDNF/TrkB signaling, neurotrophin signaling, neurological disorders, mental illness, neurotrophic therapy, neuroplasticity, cell death
MeSH terms
Animals, Mental Disorders, Humans, Nervous System, Signal Transduction, Brain-Derived Neurotrophic Factor, Receptor, trkB, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Integral Characterization of Defective BDNF/TrkB Signalling in Neurological and Psychiatric Disorders Leads the Way to New Therapies. https://app.cochat.ai/papers/10.3390/ijms18020268
The paper
Tejeda, G., & Díaz-Guerra, M. (2017). Integral Characterization of Defective BDNF/TrkB Signalling in Neurological and Psychiatric Disorders Leads the Way to New Therapies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms18020268

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.